Latest news with #Convatec
Time Business News
7 days ago
- Business
- Time Business News
Wound Care Biologics Gain Ground in Healing Complex Surgical and Trauma Wounds
The bioengineered products used for non-healing wounds of lower extremity are Wound care biologics. Usage involves of active biological agents such as plant and animal-derived biomolecules which exhibits antioxidant and antimicrobial properties. They used in the post surgeries and trauma cases as they provide moist healing environment aiding heat loss, protein, and prevent bacterial contamination. Demand for various products are also been manufactured to replace or augment various substrates in the wound healing cascade. Wound care biologic dressings are increasingly being used in post surgeries and severe trauma cases as they provide moist healing environment aiding heat loss, protein and electrolyte loss for faster healing, and prevent bacterial contamination. Key Growth Drivers and Opportunities Increasing incidence of traumatic: Growing incidences of traumatic, surgical, ulcers and burn wounds are the major driver factor of wound care biologics. In 2017, according to global diabetes community it was estimated that 422 million adults are living with diabetes globally, and this is expected to increase to 642 million by 2040. Challenges The higher cost tag associated with biologics and the tough regulatory hurdles for bringing new tissue-engineered products to market are holding back the growth of the wound care biologics sector. Smaller healthcare centers frequently find it tough to pay for or keep these cutting-edge treatments on hand, which limits patients' ability to get them. Innovation and Expansion Convatec Enters Biologics Market with Triad Life Sciences Acquisition In March 2022, Convatec Group Plc made a move by acquiring Triad Life Sciences Inc., a medical device company from the United States. Triad focused on creating products from biological sources to help heal surgical wounds, chronic wounds, and burns. For Convatec, purchasing Triad was a truly significant step. It allowed them to enter the market for biological wound care solutions, providing them with more tools to address medical needs that had previously gone unmet. MIMEDX Gains Japan Approval, Expands Global Footprint with Epifix In June 2021, MIMEDX (US) received approval from the Japanese Ministry of Health, Labour and Welfare for the commercialization of Epifix in Japan. MIMEDX, a US-based company, has received the green light from Japan's Ministry of Health, Labour and Welfare to bring Epifix to market in Japan. This news is a big deal and marks a major step forward for the company's plans to expand its reach around the world. Inventive Sparks, Expanding Markets Key players operating in the wound care biologics market includes Smith & Nephew Plc., Organogenesis, Inc., Integra Lifesciences Holdings Corporation, among others. Companies in the wound care biologics sector are focused on providing cutting-edge healing options that speed up recovery and enhance the quality of life for patients. About Author: Prophecy is a specialized market research, analytics, marketing and business strategy, and solutions company that offer strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high value opportunities in the target business area. Also, we help our client to address business challenges and provide best possible solutions to overcome them and transform their business. TIME BUSINESS NEWS
Daily Mail
04-07-2025
- Business
- Daily Mail
Shareholder revolts at FTSE 100 firms more than double
The number of FTSE 100 shareholder rebellions more than doubled in the first half of 2025 as investors increasing rejected excessive executive pay. Analysis by consultancy group Indigo shows 11 of the 56 FTSE 100 firms that held their annual general meeting between January and June faced a revolt from investors, up from just five over the same period last year. Indigo said the rise was mostly driven by resistance to executive pay packages. Seven blue-chip businesses had at least a fifth of their investors vote against their proposals on director remuneration reports or policies, compared to just three the previous year. Among the most notable examples was engineering giant Melrose Industries, the owner of automotive parts manufacturer GKN. Two-thirds of its shareholders voted at the start of May against handing more than £50million each to three former executives - Simon Peckham, Geoffrey Martin, and Christopher Miller - and £45.4million to the current CEO, Peter Dilnot. Soon after British Gas owner Centrica, whose boss Chris O'Shea once described his pay as 'impossible to justify', suffered a revolt from nearly 40 per cent of investors over its compensation plans. A fortnight later, about one-third of Convatec shareholders rejected a proposal to hike the maximum share award of the medical products maker's boss, Karim Bitar, from 300 per cent of his yearly salary to 425 per cent. Almost a quarter also opposed the establishment of a new share incentive plan. Unilever, Taylor Wimpey, InterContinental Hotels Group and London Stock Exchange Group have also experienced rebellions over executive pay. Bernadette Young, co-founder of Indigo, said: 'Boards must be prepared for heavy scrutiny of any proposals put to shareholders, but particularly in relation to emotive issues such as pay and sustainability, where investors are more likely to take a strongly principled stance.' She added that the uptick in revolts was 'indicative of the increasingly activist shareholder culture that we have seen develop in the UK in recent years'. The UK Corporate Governance Code defines a shareholder rebellion as when at least 20 per cent of a firm's shareholders vote against a board resolution at an AGM. Should this happen, company boards must detail the actions they will take to consult with investors in order to understand the reasons behind the vote. Shareholder votes on issues such as directors' remuneration are largely non-binding, meaning businesses are not legally obligated to abide by the outcome. Nonetheless, Young believes boards should 'proactively engage with shareholders and advisors before and after any major changes are made to company policies to ensure they have not misread investor sentiment and are not forced into embarrassing climbdowns or providing high-profile justifications for their actions'.
Times
12-05-2025
- Business
- Times
Convatec braces itself for investor revolt over executive pay
Leading shareholder advisory groups have raised concerns about higher, American-style executive pay at Convatec, raising the prospect of an investor revolt at its annual general meeting next week. The FTSE 100 medical equipment company is seeking shareholder approval for a new remuneration policy at its AGM, which it says comes at a critical time for its future. In 2024 Convatec posted a sixth straight year of accelerating revenue growth, following a turnaround after a troubled start as a public company in 2016, when it listed with the largest healthcare initial public offering in Europe for two decades. The board has decided to introduce a new pay policy a year ahead of schedule to 'ensure ongoing competitiveness at a key time for the organisation'. • Plus500
